Inquiry

Antibiotic Therapy R&D for IBD

It is thought that changes in the gut microbiota correlate with chronic intestinal inflammation in inflammatory bowel disease (IBD). It was caused by some pathogenic bacterial strains — highly pathogenic Escherichia coli strains, Bacteroides spp, Mycobacterium avium subspecies paratuberculosis — which has been implicated in the IBD. The course of IBD could be affected by antibiotics in many different ways: they might lower the level of bacteria in the intestinal lumen, change the makeup of the intestinal microbiota, and decrease the function of bacterial enzymes. The antibiotics being tested for IBD have been ciprofloxacin, metronidazole, combination ciprofloxacin/metronidazole, rifaximin and antituberculosis drugs.

Fig. 1. Intermittent antibiotic treatment accelerated the development of colitis in IL-10 knockout mice. (Li, et al., 2022)

Our Antibiotic Therapy R&D Services

Ace Therapeutics is a contract research organization for antibiotic therapy R&D. We seek innovative strategies to develop treatments for IBD by reducing intestinal lumen bacteria density and changing gut microbiota.

With many pharma professionals including pharmacologists, geneticists and microbiologists our team provides the right advice and support at each client's discretion. We are research-oriented — broad but deliberate — on antibiotic therapy development and analysis of the therapeutic impact of antibiotics on IBD.

Analysis of the Effects of Antibiotics on the Microbiome and the Metabolome in IBD

• We use high-throughput sequencing methods (e.g., 16S rRNA sequencing, and metagenomic sequencing approaches) to measure the changes in microbiome community structure and diversity prior to antibiotic exposure and following antibiotic exposure.
• There are mass spectrometric and nuclear magnetic resonance (NMR) capability available that we can use to measure microbial metabolites like short-chain fatty acids and amino acids pre- and post-antibiotic treatment.
• Non-culture treatment induced phylogenetic analysis of gut microbiome enables much better exploration of how antibiotic therapies change microbiome and facilitation of mechanistic understanding.

Evaluation of the Efficacy of Antibiotic Therapies in IBD

We offer several test for whether antibiotic treatment for IBD is therapeutically effective in animal models of colitis.

• Symptoms of colitis — animal weight gain, feeding/water intake, overall health, presence of unique colitis are measured to assess the effect of antibiotics.
• Colon length, colon weight, cecum weight, spleen weight, liver weight, kidney weight can be done to calculate the effect of the antibiotics on animal's physiological parameters.
• Antibiotics effect colonic integrity and mucosal barrier function in animals by histopathological assessment, thickness of colonic mucus, intestinal permeability measurement, and protein expression for barrier function-associated protein.

Ace Therapeutics provides quality antibiotic therapy development services to IBD research pharmaceutical companies based on technology and experience. Our solutions help our customers get critical information by examining how antibiotics change the microbiome and metabolome. To know more about us, get in touch with us.